Can Borrelia IgM indicate recent infection timing or current viable infection?

Borrelia IgM is best understood as evidence of an antibody response, not a clock for infection timing or a test of organism viability. Its clinical value is greatest early in a compatible illness and falls substantially when interpreted in isolation or late in the symptom course.

Clinical interpretation

• IgM commonly becomes detectable about 2–4 weeks after symptom onset. In culture-confirmed erythema migrans, 91% had a positive ELISA and/or IgM immunoblot by days 8–14, making early reactivity biologically compatible with recent Borrelia antigen recognition.
• Recommended two-tier testing limits interpretation of an IgM immunoblot to symptoms lasting ≤30 days. After 30 days, isolated IgM should be disregarded because it is more likely to reflect persistence or false positivity than active Lyme disease.
• An IgM result alone cannot determine when infection occurred, establish treatment failure or reinfection, or demonstrate current viable organisms.

Persistence and false positivity

• Persistent IgM is well documented: at 10–20 years after treated Lyme disease, IgM remained detectable in 4/40 (10%) people with prior early disease and 6/39 (15%) with prior Lyme arthritis, despite no active disease.
• Cross-reactivity and nonspecific immune activation can produce Borrelia-reactive IgM. Recognized contributors include relapsing fever, syphilis, Epstein–Barr virus, parvovirus B19, CMV, rheumatoid arthritis, and autoimmune antibodies.
• In low-pretest-probability settings, misleading positives are clinically important: one North Carolina cohort found compatible active Lyme disease in only 12/70 two-tier-positive patients (positive predictive value 17%; 10% without travel to an endemic region).

Mechanistic implications

• Serology detects host antibody production and immunologic memory, not living spirochetes. Even PCR detects DNA rather than viability, and blood PCR has limited sensitivity because spirochetemia is transient.

Bottom line

• The claim is well supported: early, contextually appropriate IgM may suggest recent antigen recognition, but persistent and cross-reactive IgM means it cannot alone date infection or prove ongoing viable Borrelia infection.